Akèy › Kansè nan tete › Georgia
Etid klinik pou Kansè nan tete nan Georgia
53 etid pou Kansè nan tete ap chèche patisipan nan sit nan Georgia.
Vil nan Georgia
- Atlanta41 etid
- Savannah11 etid
- South Fulton5 etid
- Augusta5 etid
- Athens5 etid
- Johns Creek4 etid
- Gainesville3 etid
- Sandy Springs3 etid
Tèks ofisyèl etid la (Anglè)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- ak 4 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Winship Cancer Institute, Emory University, Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Emory Proton Therapy Center, Atlanta
Ap rekriteFaz 3
Laj 19 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05856773A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Emory University Hospital, Atlanta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05646862A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Emory University Winship Cancer Institute, Atlanta
- Liberty County Cancer Care, Hinesville
- Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
- ak 2 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Marietta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
- Central Georgia Cancer Care, Macon
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Winship Cancer Institute, Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Winship Cancer Institute of Emory University, Atlanta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- University Blood & Cancer Center, LLC, Athens
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05570253A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Summit Cancer Care, Savannah
Ap rekriteFaz 1
Laj 18 a 55 · Fanm · Mizajou Sep 9, 2026 · NCT07310420A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Marietta
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 8, 2026 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07100106A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Atlanta Cancer Care - Northside Hospital, Atlanta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT05846789A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Northwest Georgia Oncology Centers PC - Marietta, Marietta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phoebe Putney Memorial Hospital, Albany
- University Cancer and Blood Center LLC, Athens
- Grady Health System, Atlanta
- ak 16 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Winship Cancer Institute of Emory University, Atlanta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Augusta University, Augusta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06764940Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
- Emory University Hospital/Winship Cancer Institute, Atlanta
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764796Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Winship Cancer Institute at Emory University, Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06263543FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Emory University, Atlanta
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT05304962A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Atlanta, Newnan
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 6, 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- ak 3 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Emory University, Atlanta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07288359First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Atlanta
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04641247Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Emory University School of Medicine, Atlanta
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT05696626Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- Emory University Hospital/Winship Cancer Institute, Atlanta
Ap rekriteVolontè an sante akeyi
Laj 25 ak plis · Fanm · Mizajou May 26, 2026 · NCT06760507Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Fanm · Mizajou May 7, 2026 · NCT05877859Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.